The Hypothesis

The failure of young-to-aged fecal microbiota transplantation (FMT) to stick long-term isn't just a problem with microbial seeding. Instead, I’d argue it’s a consequence of what I call the Adipose-Enteric Feedback Lock (AEFL). In this model, visceral adipose tissue (VAT) acts as an extra-intestinal "immunological warden." Established senescent-associated secretory phenotype (SASP) factors from visceral fat—specifically TNF-α and IL-1β—function as persistent signals that block the restoration of the intestinal barrier, regardless of what microbes we introduce. This creates a physiological lock: inflamed fat mandates a "leaky" gut, which then ensures the microbiome quickly reverts to a dysbiotic state.

Mechanistic Reasoning

Most current research focuses on the gut as the primary driver of inflammaging via LPS translocation [https://pmc.ncbi.nlm.nih.gov/articles/PMC8054695/]. However, that overlooks the "slow-motion immune war" happening in the adipose tissue. By the time an organism reaches late senescence, the VAT is no longer just a passive responder to gut endotoxins; it's an autonomous inflammatory organ.

While young FMT can temporarily boost beneficial metabolites like butyrate [https://www.imrpress.com/journal/JMCM/8/1/10.31083/JMCM40022/], these local signals aren't strong enough to overcome the systemic cytokine load generated by aged fat. Specifically, fat-derived cytokines target tight junction proteins like zonulin and occludin. As long as the VAT stays dominated by pro-inflammatory M1 macrophages and senescent cells, the gut barrier can't fully "seal." This persistent permeability allows for continued low-grade endotoxemia, creating a selective pressure that favors the regrowth of pathobionts. It’s why FMT recipients often revert to aged profiles within a few months [https://pmc.ncbi.nlm.nih.gov/articles/PMC12233830/].

Addressing the "Persistence Trap"

The AEFL hypothesis helps explain the "Persistence Trap" where a young microbiome remains metabolically incompatible with an environment defined by high systemic inflammation. If the gut is a warehouse, we're essentially trying to restock the shelves while the building's structural integrity is being actively undermined by a fire next door. This also clarifies why FMT works better in middle-aged hosts [https://pubmed.ncbi.nlm.nih.gov/PMC12096931]: at that stage, the adipose immune war is still in an early phase, and the feedback lock hasn't reached a point of irreversible systemic inertia.

Testability and Falsification

We can test this by decoupling adipose inflammation from gut composition.

1. Experimental Group: Aged mice undergo senolytic depletion of p16-positive cells specifically in visceral adipose tissue (using targeted delivery) before receiving a young-to-aged FMT.
2. Control Group: Aged mice receive young-to-aged FMT alone.
3. Prediction: The adipose-senolytic group will show significantly higher FMT engraftment durability at the six-month mark and better restoration of intestinal barrier markers than the control.

Falsification: If adipose senolysis doesn't improve FMT durability, or if the gut barrier restores perfectly after FMT regardless of fat inflammation, the AEFL hypothesis is wrong. But if adipose-targeted interventions turn out to be the sine qua non for microbiome persistence, we'll have to move away from gut-centric models toward a more integrated, multi-organ view of metabolic rejuvenation [https://pmc.ncbi.nlm.nih.gov/articles/PMC11320341/].